March was a consequential month. PwC published a detailed analysis of the women’s health market, making the case plainly: women’s health is one of the most undercapitalized growth markets in healthcare today and the gap is not simply one of equity but reflects a structural inefficiency in how healthcare markets have been defined and funded.
That same week, BioXconomy reported that only 1% of healthcare research and innovation funding is allocated to female-specific conditions outside of oncology while noting that venture capital into the space rose 55% in 2024. The gap and the momentum, documented in the same breath.
That is what reminded me, again, why this work matters. Not the validation but the signal.